Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem unloaded 29,500 shares of Edwards Lifesciences Corp stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $98.14, for a total transaction of $2,895,130.00. Following the completion of the transaction, the chief executive officer now directly owns 263,850 shares in the company, valued at approximately $25,894,239. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on EW shares. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $104.00 price target on the stock. Separately, analysts at JMP Securities raised their price target on shares of Edwards Lifesciences Corp from $97.00 to $120.00 in a research note on Thursday, August 21st. They now have an “outperform” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $92.24.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 0.76% on Thursday, hitting $98.26. The stock had a trading volume of 619,598 shares. Edwards Lifesciences Corp has a 52-week low of $60.62 and a 52-week high of $99.35. The stock has a 50-day moving average of $91.97 and a 200-day moving average of $81.62. The company has a market cap of $10.419 billion and a price-to-earnings ratio of 14.07.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp will post $3.29 EPS for the current fiscal year.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.